Clinical trial · Observational
DCE-MRI for Assessment of Response to TACE of HCC
Dynamic Contrast-enhanced Magnetic Resonance Imaging for Assessment of Response to Transarterial Chemoembolization of Hepatocellular Carcinoma
NCT02878109CI-TRIAL-00053135DCE-MRIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at blow flow curves of the free-breathing MRI before treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Post-treatment phase group | Device | — | UNRESOLVED |
| Pre-treatment phase group | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Post-treatment phase group
- description
- 29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
- interventionNames
- Device: Post-treatment phase group
- label
- Pre-treatment phase group
- description
- 11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
- interventionNames
- Device: Pre-treatment phase group
Primary outcomes (2)
- measure
- Hepatic and tumor blood flow before and after TACE
- timeFrame
- Within 2 weeks before TACE and 6 to 8 weeks after TACE
- description
- Measures of hepatic and tumor blood flow will help in describing HCC angiogenesis and in determining the efficiency of TACE on the tumor.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients: * Are at least 18 years old at screening; * Able to comprehend and willingness to provide voluntary consent; * Have at least one HCC; * HCC lesion of at least 10 mm; * Understand French or English instruction. * Post-treament phase group: * Are able to have a MRI before and after TACE; * Must undergo a TACE as part of their clinical standard of care for HCC; * Have a new prescription for TACE for at least one HCC. * Pre-treatment phase group: * Are able to have a MRI before treatment (if any); * Must undergo an MRI as part of their clinical standard of care for HCC. Exclusion Criteria: * Have any contra-indication for MRI (such as claustrophobia, pacemaker, metallic clips for a neurosurgical procedure); * Are pregnant or trying to become pregnant; * Have a weight or girth preventing them from entering the MR magnet bore; * Are unable to understand or unwilling to provide written informed consent for this study.
References
Publications (0)
Data not yet available
No reference posted for this study.